National Heart & Lung Institute (A.S.L., P.T., R.W., S.S., B.P.H., U.T., A.d.M., A.I., M.Y., M.J.H., R.E.J., R.W., R.B., M.N., J.L.R., A.P., J.G.F.C., P.J.R.B., D.J.P., J.S.W., S.K.P.), Imperial College London, UK.
Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK (A.S.L., P.T., R.W., S.S., B.P.H., U.T., A.d.M., A.I., M.Y., M.J.H., R.E.J., R.W., R.B., F.V., Y.H., T.M., J.W., J.L.R., A.J.B., A.P., P.J.R.B., D.J.P., J.S.W., S.K.P.).
Circulation. 2022 Oct 11;146(15):1123-1134. doi: 10.1161/CIRCULATIONAHA.121.058457. Epub 2022 Sep 26.
Acute myocarditis is an inflammatory condition that may herald the onset of dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM). We investigated the frequency and clinical consequences of DCM and ACM genetic variants in a population-based cohort of patients with acute myocarditis.
This was a population-based cohort of 336 consecutive patients with acute myocarditis enrolled in London and Maastricht. All participants underwent targeted DNA sequencing for well-characterized cardiomyopathy-associated genes with comparison to healthy controls (n=1053) sequenced on the same platform. Case ascertainment in England was assessed against national hospital admission data. The primary outcome was all-cause mortality.
Variants that would be considered pathogenic if found in a patient with DCM or ACM were identified in 8% of myocarditis cases compared with <1% of healthy controls (=0.0097). In the London cohort (n=230; median age, 33 years; 84% men), patients were representative of national myocarditis admissions (median age, 32 years; 71% men; 66% case ascertainment), and there was enrichment of rare truncating variants (tv) in ACM-associated genes (3.1% of cases versus 0.4% of controls; odds ratio, 8.2; =0.001). This was driven predominantly by -tv in patients with normal LV ejection fraction and ventricular arrhythmia. In Maastricht (n=106; median age, 54 years; 61% men), there was enrichment of rare truncating variants in DCM-associated genes, particularly -tv, found in 7% (all with left ventricular ejection fraction <50%) compared with 1% in controls (odds ratio, 3.6; =0.0116). Across both cohorts over a median of 5.0 years (interquartile range, 3.9-7.8 years), all-cause mortality was 5.4%. Two-thirds of deaths were cardiovascular, attributable to worsening heart failure (92%) or sudden cardiac death (8%). The 5-year mortality risk was 3.3% in genotype-negative patients versus 11.1% for genotype-positive patients (=0.08).
We identified DCM- or ACM-associated genetic variants in 8% of patients with acute myocarditis. This was dominated by the identification of -tv in those with normal left ventricular ejection fraction and -tv in those with reduced left ventricular ejection fraction. Despite differences between cohorts, these variants have clinical implications for treatment, risk stratification, and family screening. Genetic counseling and testing should be considered in patients with acute myocarditis to help reassure the majority while improving the management of those with an underlying genetic variant.
急性心肌炎是一种炎症性疾病,可能预示着扩张型心肌病(DCM)或心律失常性心肌病(ACM)的发作。我们研究了在一个基于人群的急性心肌炎患者队列中,DCM 和 ACM 遗传变异的频率和临床后果。
这是一个基于人群的队列研究,共纳入 336 例连续急性心肌炎患者,分别来自伦敦和马斯特里赫特。所有参与者均接受了针对已知与心肌病相关的基因的靶向 DNA 测序,并与在同一平台上测序的 1053 例健康对照者进行了比较。在英格兰,通过与国家住院数据进行比较来确定病例发现情况。主要结局为全因死亡率。
在心肌炎患者中发现 DCM 或 ACM 相关致病性变异的比例为 8%,而在健康对照组中不到 1%(=0.0097)。在伦敦队列(n=230;中位年龄 33 岁;84%为男性)中,患者与全国心肌炎入院患者具有代表性(中位年龄 32 岁;71%为男性;66%的病例发现),并且在 ACM 相关基因中存在丰富的罕见截断变异(tv)(3.1%的病例与 0.4%的对照组;比值比,8.2;=0.001)。这主要是由于左心室射血分数正常和室性心律失常患者的 ACM 相关基因中的 -tv 引起的。在马斯特里赫特队列(n=106;中位年龄 54 岁;61%为男性)中,DCM 相关基因中的罕见截断变异,特别是 -tv,也有富集,发现比例为 7%(均伴有左心室射血分数<50%),而对照组为 1%(比值比,3.6;=0.0116)。在中位随访时间为 5.0 年(四分位距,3.9-7.8 年)的两个队列中,全因死亡率为 5.4%。三分之二的死亡是心血管原因,归因于心力衰竭恶化(92%)或心源性猝死(8%)。基因型阴性患者的 5 年死亡率为 3.3%,而基因型阳性患者为 11.1%(=0.08)。
我们在 8%的急性心肌炎患者中发现了 DCM 或 ACM 相关的遗传变异。这主要是由于左心室射血分数正常的患者存在 -tv,以及左心室射血分数降低的患者存在 -tv。尽管两个队列之间存在差异,但这些变异对治疗、风险分层和家族筛查具有临床意义。对于急性心肌炎患者,应考虑进行遗传咨询和检测,以帮助大多数患者安心,同时改善那些存在潜在遗传变异的患者的治疗效果。